The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
CONCLUSION: We recommend using the Patient Motivation Pyramid as structural approach for identifying elements of patient-centricity. Secondly we recommend to start using patient-centric approaches in an early phase of the medicine's lifecycle.PMID:33906590 | DOI:10.2174/1574884716666210427115820 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 28, 2021 Category: Drugs & Pharmacology Authors: Thijs van Iersel Jocelyn Courville Cathalijne van Doorne Remco A Koster Christina Fawcett Source Type: research
Immune checkpoint inhibitors in the treatment of cancer
CONCLUSION: This review also highlighted the most common adverse effects caused by ICIs and which affect people in different ways.PMID:33823768 | DOI:10.2174/1574884716666210325095022 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 7, 2021 Category: Drugs & Pharmacology Authors: Wissam Zam Lina Ali Source Type: research
Immune checkpoint inhibitors in the treatment of cancer
CONCLUSION: This review also highlighted the most common adverse effects caused by ICIs and which affect people in different ways.PMID:33823768 | DOI:10.2174/1574884716666210325095022 (Source: Current Clinical Pharmacology)
Source: Current Clinical Pharmacology - April 7, 2021 Category: Drugs & Pharmacology Authors: Wissam Zam Lina Ali Source Type: research
